Beam Therapeutics (BEAM) AI Stock Analysis

• Market Cap: $2.72B
• Dividend Yield: N/A
• Average Volume (3M): 1.94M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.09
• Revenue Growth: -84.07%
• EPS Growth: -157.71%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.10
• Shares Outstanding: 101,474,945
• 10 Day Avg. Volume: 1,805,758
• 30 Day Avg. Volume: 1,940,031
• PEG Ratio: -0.03
• Price to Book (P/B): 2.78
• Price to Sales (P/S): 32.14
• P/FCF Ratio: -5.73
• Enterprise Value/Market Cap: 0.58
• Enterprise Value/Revenue: 28.11
• Enterprise Value/Gross Profit: -4.40
• Enterprise Value/Ebitda: -3.64
• 1Y Price Target: $43.00
• Price Target Upside: 60.69% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): -4.47
• Revenue Forecast (FY): $37.36M

• Rating: 58 Neutral
• Price Target: $28.00 ▲(4.63% Upside)

Beam Therapeutics' overall stock score is primarily influenced by its weak financial performance, characterized by significant losses and negative cash flows. However, the stock shows positive technical indicators, suggesting potential short-term price appreciation. The recent corporate event, resulting in a substantial cash gain, provides a positive outlook and liquidity boost. Despite these positives, the negative valuation metrics reflect ongoing profitability challenges, keeping the overall score moderate.

Positive Factors

Innovative Gene Editing Technology

Beam's proprietary base editing technology positions it as a leader in precision genetic medicine, offering a competitive advantage in treating genetic disorders.

Recent Clinical Trial Success

Positive clinical trial results for BEAM-101 demonstrate potential efficacy in treating sickle cell disease, enhancing Beam's product pipeline and market position.

Cash Infusion from Orbital Acquisition

The cash gain from Orbital acquisition strengthens Beam's balance sheet, providing liquidity to support ongoing R&D and operational activities.

Negative Factors

Declining Revenue and Profitability

Ongoing revenue decline and negative profitability highlight operational challenges, potentially impacting long-term financial health and sustainability.

Negative Cash Flow

Negative cash flow growth indicates financial strain, limiting Beam's ability to invest in growth opportunities and maintain operational flexibility.

High Net Profit Margin Loss

A deeply negative net profit margin reflects severe financial losses, challenging Beam's path to profitability and long-term viability.

Beam Therapeutics Business Overview & Revenue Model

Company Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

How the Company Makes Money

Beam Therapeutics generates revenue through a combination of research and development collaborations, licensing agreements, and potential future product sales. The company partners with pharmaceutical companies and research institutions to co-develop its therapies, often receiving upfront payments, milestone payments as projects advance, and royalties on future sales. Additionally, Beam may monetize its proprietary technologies through licensing deals, allowing other companies to use their base editing technology in exchange for fees. As their product candidates advance through clinical trials and toward commercialization, potential sales of successful therapies will also contribute to revenue.

Beam Therapeutics Financial Statement Overview

Summary

Beam Therapeutics faces significant financial challenges, with declining revenues, substantial losses, and negative cash flows. The company has a manageable debt level, but profitability and cash flow issues persist. While there are some signs of potential revenue growth, the overall financial health is weak, requiring strategic improvements to achieve stability and profitability.

Income Statement

Beam Therapeutics has experienced declining revenue and negative profit margins over the TTM period. The company shows a negative revenue growth rate of -7.58% and a significant net profit margin of -901.34%, indicating substantial losses. The EBIT and EBITDA margins are also deeply negative, reflecting operational challenges. Despite these issues, the company has shown some historical revenue growth, suggesting potential for future improvement.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.16, indicating a relatively low level of leverage. However, the return on equity is negative at -42.86%, reflecting ongoing losses. The equity ratio is not explicitly calculated, but the company maintains a reasonable level of stockholders' equity relative to its total assets, suggesting some financial stability despite profitability challenges.

Cash Flow

Beam Therapeutics has negative operating and free cash flows, with a free cash flow growth rate of -90.3% over the TTM period. The operating cash flow to net income ratio is -1.85, indicating cash flow challenges. However, the free cash flow to net income ratio is slightly positive at 1.04, suggesting some ability to cover net losses with free cash flow, albeit limited.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	55.70M	63.52M	377.71M	60.92M	51.84M	24.00K
Gross Profit	-356.09M	-304.04M	377.71M	-250.67M	-180.29M	-103.16M
EBITDA	-430.13M	-393.64M	-146.95M	-324.33M	-230.06M	-128.03M
Net Income	-414.64M	-376.74M	-132.53M	-289.09M	-370.64M	-194.59M
Balance Sheet
Total Assets	1.31B	1.10B	1.46B	1.34B	1.47B	451.68M
Cash, Cash Equivalents and Short-Term Investments	1.07B	850.74M	1.19B	1.08B	965.65M	299.67M
Total Debt	151.42M	161.43M	172.69M	179.00M	147.64M	107.64M
Total Liabilities	345.08M	370.28M	478.38M	608.24M	647.72M	206.12M
Stockholders Equity	966.00M	733.54M	981.33M	733.47M	826.74M	245.56M
Cash Flow
Free Cash Flow	-352.36M	-356.19M	-182.93M	-26.42M	-113.08M	-112.10M
Operating Cash Flow	-338.18M	-347.25M	-149.19M	22.53M	-66.27M	-95.74M
Investing Cash Flow	-103.56M	185.01M	71.84M	-461.34M	-294.14M	-100.12M
Financing Cash Flow	479.61M	7.74M	276.45M	111.59M	756.14M	322.32M

Beam Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 26.76
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BEAM, the sentiment is Positive. The current price of 26.76 is above the 20-day moving average (MA) of 25.38, above the 50-day MA of 25.17, and above the 200-day MA of 20.99, indicating a bullish trend. The MACD of 0.80 indicates Negative momentum. The RSI at 50.61 is Neutral, neither overbought nor oversold. The STOCH value of 29.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BEAM.

Beam Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	60 Neutral	$3.49B	-79.94	-28.17%	―	129.21%	80.35%
BEAM	58 Neutral	$2.72B	―	-47.19%	―	-84.07%	-157.71%
IMCR	53 Neutral	$1.83B	-61.31	-7.52%	―	27.51%	38.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DNLI	45 Neutral	$2.66B	-5.77	-44.44%	―	―	-5.30%
IMVT	45 Neutral	$5.36B	-9.54	-95.93%	―	―	-27.70%
IRON	43 Neutral	$3.45B	-16.33	-34.78%	―	―	-34.96%

Beam Therapeutics Corporate Events

Beam Therapeutics Gains $255M from Orbital Acquisition

On December 8, 2025, Bristol-Myers Squibb completed its acquisition of Orbital Therapeutics, in which Beam Therapeutics held a 17% stake. Beam’s shares were converted into $255.1 million in cash, with potential for additional consideration, impacting its financial outlook ahead of the 2026 J.P. Morgan Healthcare Conference.